Open Access
| Issue |
J Extra Corpor Technol
Volume 58, Number 1, March 2026
|
|
|---|---|---|
| Page(s) | 57 - 64 | |
| DOI | https://doi.org/10.1051/ject/2025045 | |
| Published online | 13 March 2026 | |
- Chaves R, Rabello Filho R, Timenetsky K, et al. Extracorporeal membrane oxygenation: a literature review. Rev Bras Ter Intensiva. 2019;31(3):410–424. [Google Scholar]
- Ratnani I, Tuazon D, Zainab A, Uddin F. The role and impact of Extracorporeal Membrane Oxygenation in critical care. Methodist Debakey Cardiovasc J. 2018;14(2):110–119. [Google Scholar]
- Makdisi G, Wang I. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015;7(7):E166–E176. [PubMed] [Google Scholar]
- Burstein B, Wieruszewski P, Zhao Y, Smischney N. Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation. World J Crit Care Med. 2019;8(6):87–98. [CrossRef] [PubMed] [Google Scholar]
- McMichael A, Ryerson L, Ratano D, Fan E, Faraoni D, Annich G. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2022;68(3):303–310. [CrossRef] [PubMed] [Google Scholar]
- Rivosecchi R, Arakelians A, Ryan J, et al. Comparison of anticoagulation strategies in patients requiring venovenous extracorporeal membrane oxygenation: Heparin versus bivalirudin. Crit Care Med. 2021;49:1129–1136. [Google Scholar]
- Ranucci M, Ballotta A, Kandil H, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275. [CrossRef] [PubMed] [Google Scholar]
- Sanfilippo F, Asmussen S, Maybauer D, et al. Bivalirudin for alternative anticoagulation in extracorporeal membrane oxygenation: A systematic review. J Inten Care Med. 2017;32(5):312–319. [Google Scholar]
- Netley J, Roy J, Greenlee J, et al. Bivalirudin anticoagulation dosing protocol for extracorporeal membrane oxygenation: A retrospective review. J Extra Corpor Technol. 2018;50:161–166. [Google Scholar]
- Kaseer H, Soto-Arenall M, Sanghavi D, et al. Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation. J Card Sug. 2020;35:779–786. [Google Scholar]
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314. [Google Scholar]
- Trigonis R, Smith N, Porter S, et al. Efficacy of bivalirudin for therapeutic anticoagulation in COVID-19 patients requiring ECMO support. J Cardiothorac Vasc Anesth. 2022;36:414–418. [CrossRef] [Google Scholar]
- Bissell B, Gabbard T, Sheridan E, et al. Evaluation of bivalirudin as the primary anticoagulant in patients receiving extracorporeal membrane oxygenation for SARS-CoV-2-associated acute respiratory failure. Ann Pharmacother, 2022;56(4):387–392. [CrossRef] [PubMed] [Google Scholar]
- Silva B, Cordioli R, Santos B, et al. COVID-19-associated coagulopathy and acute kidney injury in critically ill patients. Einstein. 2023;21:eAO0119. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.